Japan has a longstanding relationship with immuno-oncology. In 1992, Japanese research scientists first discovered the programmed cell death-1 (PD-1) target. Since then, the T-cell receptor has received an influx of attention from drug developers seeking to use checkpoint inhibitors to stop cancer in its tracks.